» Articles » PMID: 35279104

A Novel Nine-microRNA-based Model to Improve Prognosis Prediction of Renal Cell Carcinoma

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Mar 13
PMID 35279104
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the improved knowledge of disease biology and the introduction of immune checkpoints, there has been significant progress in treating renal cell carcinoma (RCC) patients. Individual treatment will differ according to risk stratification. As the clinical course varies in RCC, it has developed different predictive models for assessing patient's individual risk. However, among other prognostic scores, no transparent preference model was given. MicroRNA as a putative marker shown to have prognostic relevance in RCC, molecular analysis may provide an innovative benefit in the prophetic prediction and individual risk assessment. Therefore, this study aimed to establish a prognostic-related microRNA risk score model of RCC and further explore the relationship between the model and the immune microenvironment, immune infiltration, and immune checkpoints. This practical model has the potential to guide individualized surveillance protocols, patient counseling, and individualized treatment decision for RCC patients and facilitate to find more immunotherapy targets.

Methods: Downloaded data of RCC from the TCGA database for difference analysis and divided it into a training set and validation set. Then the prognostic genes were screened out by Cox and Lasso regression analysis. Multivariate Cox regression analysis was used to establish a predictive model that divided patients into high-risk and low-risk groups. The ENCORI online website and the results of the RCC difference analysis were used to search for hub genes of miRNA. Estimate package and TIMER database were used to evaluate the relationship between risk score and tumor immune microenvironment (TME) and immune infiltration. Based on Kaplan-Meier survival analysis, search for immune checkpoints related to the prognosis of RCC.

Results: There were nine miRNAs in the established model, with a concordance index of 0.702 and an area under the ROC curve of 0.701. Nine miRNAs were strongly correlated with the prognosis (P < 0.01), and those with high expression levels had a poor prognosis. We found a common target gene PDGFRA of hsa-miR-6718, hsa-miR-1269b and hsa-miR-374c, and five genes related to ICGs (KIR2DL3, TNFRSF4, LAG3, CD70 and TNFRSF9). The immune/stromal score, immune infiltration, and immune checkpoint genes of RCC were closely related to its prognosis and were positively associated with a risk score.

Conclusions: The established nine-miRNAs prognostic model has the potential to facilitate prognostic prediction. Moreover, this model was closely related to the immune microenvironment, immune infiltration, and immune checkpoint genes of RCC.

Citing Articles

Emerging Roles of ncRNAs in Type 2 Diabetes Mellitus: From Mechanisms to Drug Discovery.

Yang Y, Cheng H Biomolecules. 2024; 14(11).

PMID: 39595541 PMC: 11592034. DOI: 10.3390/biom14111364.


Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma.

Wei G, Wei X, Fan L, Zhou W, Sun M, Zhu C World J Clin Oncol. 2024; 15(10):1280-1292.

PMID: 39473860 PMC: 11514508. DOI: 10.5306/wjco.v15.i10.1280.


Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes.

Malar D, Verma K, Prasanth M, Tencomnao T, Brimson J Sci Rep. 2024; 14(1):4328.

PMID: 38383841 PMC: 10882047. DOI: 10.1038/s41598-024-55013-9.

References
1.
Kong X, Lv Y, Shao L, Nong X, Zhang G, Zhang Y . HBx-induced MiR-1269b in NF-κB dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. J Transl Med. 2016; 14(1):189. PMC: 4924318. DOI: 10.1186/s12967-016-0949-y. View

2.
Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L . Immune infiltration in renal cell carcinoma. Cancer Sci. 2019; 110(5):1564-1572. PMC: 6501001. DOI: 10.1111/cas.13996. View

3.
Chowdhury N, Drake C . Kidney Cancer: An Overview of Current Therapeutic Approaches. Urol Clin North Am. 2020; 47(4):419-431. DOI: 10.1016/j.ucl.2020.07.009. View

4.
Zhao X, Ao Y, Chen H, Wang H . [The role of miRNA in kidney development]. Yi Chuan. 2020; 42(11):1062-1072. DOI: 10.16288/j.yczz.20-112. View

5.
Ferragut Cardoso A, Udoh K, States J . Arsenic-induced changes in miRNA expression in cancer and other diseases. Toxicol Appl Pharmacol. 2020; 409:115306. PMC: 7772821. DOI: 10.1016/j.taap.2020.115306. View